Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.

MLA

Kobayashi, Hiroshi, et al. “Systemic Inflammation Response Index (SIRI) as a Predictive Factor for Overall Survival in Advanced Soft Tissue Sarcoma Treated with Eribulin.” Journal of Orthopaedic Science, vol. 27, no. 1, Jan. 2022, pp. 222–28. EBSCOhost, https://doi.org/10.1016/j.jos.2020.11.006.

APA

Kobayashi, H., Okuma, T., Okajima, K., Ishibashi, Y., Zhang, L., Hirai, T., Ohki, T., Ikegami, M., Sawada, R., Shinoda, Y., Akiyama, T., Goto, T., & Tanaka, S. (2022). Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin. Journal of Orthopaedic Science, 27(1), 222–228. https://doi.org/10.1016/j.jos.2020.11.006

Chicago

Kobayashi, Hiroshi, Tomotake Okuma, Koichi Okajima, Yuki Ishibashi, Liuzhe Zhang, Toshihide Hirai, Takahiro Ohki, et al. 2022. “Systemic Inflammation Response Index (SIRI) as a Predictive Factor for Overall Survival in Advanced Soft Tissue Sarcoma Treated with Eribulin.” Journal of Orthopaedic Science 27 (1): 222–28. doi:10.1016/j.jos.2020.11.006.